A St. Louis
University dermatologist is leading a study to see if a
prescription drug approved for cosmetic use to grow longer and
fuller lashes will stimulate eyelash regrowth for cancer
patients who lost hair from chemotherapy.
Eyelashes can take much longer than scalp
hair to grow back because they have a short growth and long
dormant phase. The drug, Latisse, keeps them in a growth
phase.
"We want to get people back into being
themselves in the way they feel and how they look," said
SLU professor of dermatology Dr. Dee Anna Glaser. "The
lack of eyelashes can be a painful reminder that they still
aren't back into their normal routines."
The drug was originally developed to treat
glaucoma, and its eyelash-boosting power was discovered by
accident. The drug's maker, Allergan, gained approval from the
Food and Drug Administration nearly a year ago for its
cosmetic use. Latisse is a clear liquid applied with a small
brush to the base of the upper lid much like eyeliner.
Allergan is providing funding for nine
research institutions, including SLU, to study whether Latisse
can benefit recovering cancer patients. Researchers will
follow patients for a year.
But the study comes after Allergan has come
under fire by the FDA and Consumer Reports for omitting or
minimizing certain risks in its promotional materials. The FDA
sent the company a warning letter in September. The drug,
which costs about $100 a month, can make hair grow in unwanted
places around the eye; cause darkening of the lower and upper
eyelids; produce itchy, red eyes and turn blue or hazel eyes
brown. Eyelashes also return to normal when you stop using it.
Glaser, who also served as a lead researcher
for the cosmetic approval of Latisse, said less than 4 percent
of study participants had eye redness. Other side effects
occurred even less frequently. She also said eye color
sometimes changed when the drug was dropped directly on the
eyeball in higher doses to treat glaucoma.
"It's something we definitely discuss
with patients so they are aware," she said.
To take part in the study, participants must
be at least 18 years old and have completed chemotherapy for
early-stage breast cancer, colorectal cancer or lymphoma
within the past four to 12 weeks. Researchers will cover the
costs of the drug and eye exams as well as provide
compensation for time and travel. For more information, call
314-256-3436.